• Syndax outlined growth plans built around Revuforj (revumenib) in acute leukemia, Niktimvo (axatilimab) in chronic GVHD, pipeline expansion.
• Revuforj and Niktimvo were annualizing at about $200 million each as of 1Q26, supporting a push toward profitability.
• Revuforj positioned as the first menin inhibitor targeting frontline AML; regulatory submission targeted for 4Q26.
• Pipeline build-out highlighted SNDX-4321, a mutant-selective allosteric EGFR inhibitor for EGFR-mutant NSCLC, targeting an IND submission in 2027.
• Next-generation menin program led by SNDX-62122 for myelofibrosis, targeting an IND submission in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.